Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

1.

RSV hijacks cellular protein phosphatase 1 to regulate M2-1 phosphorylation and viral transcription.

Richard CA, Rincheval V, Lassoued S, Fix J, Cardone C, Esneau C, Nekhai S, Galloux M, Rameix-Welti MA, Sizun C, Eléouët JF.

PLoS Pathog. 2018 Feb 28;14(3):e1006920. doi: 10.1371/journal.ppat.1006920. eCollection 2018 Mar.

2.

Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism.

Cagno V, Andreozzi P, D'Alicarnasso M, Jacob Silva P, Mueller M, Galloux M, Le Goffic R, Jones ST, Vallino M, Hodek J, Weber J, Sen S, Janeček ER, Bekdemir A, Sanavio B, Martinelli C, Donalisio M, Rameix Welti MA, Eleouet JF, Han Y, Kaiser L, Vukovic L, Tapparel C, Král P, Krol S, Lembo D, Stellacci F.

Nat Mater. 2018 Feb;17(2):195-203. doi: 10.1038/nmat5053. Epub 2017 Dec 18.

PMID:
29251725
3.

Modular cell-based platform for high throughput identification of compounds that inhibit a viral interferon antagonist of choice.

Vasou A, Paulus C, Narloch J, Gage ZO, Rameix-Welti MA, Eléouët JF, Nevels M, Randall RE, Adamson CS.

Antiviral Res. 2018 Feb;150:79-92. doi: 10.1016/j.antiviral.2017.10.012. Epub 2017 Oct 14.

4.

Functional organization of cytoplasmic inclusion bodies in cells infected by respiratory syncytial virus.

Rincheval V, Lelek M, Gault E, Bouillier C, Sitterlin D, Blouquit-Laye S, Galloux M, Zimmer C, Eleouet JF, Rameix-Welti MA.

Nat Commun. 2017 Sep 15;8(1):563. doi: 10.1038/s41467-017-00655-9.

5.

Respiratory Syncytial Virus Infects Regulatory B Cells in Human Neonates via Chemokine Receptor CX3CR1 and Promotes Lung Disease Severity.

Zhivaki D, Lemoine S, Lim A, Morva A, Vidalain PO, Schandene L, Casartelli N, Rameix-Welti MA, Hervé PL, Dériaud E, Beitz B, Ripaux-Lefevre M, Miatello J, Lemercier B, Lorin V, Descamps D, Fix J, Eléouët JF, Riffault S, Schwartz O, Porcheray F, Mascart F, Mouquet H, Zhang X, Tissières P, Lo-Man R.

Immunity. 2017 Feb 21;46(2):301-314. doi: 10.1016/j.immuni.2017.01.010.

6.

A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.

Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02241-16. doi: 10.1128/AAC.02241-16. Print 2017 Apr.

7.

RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine.

Hervé PL, Deloizy C, Descamps D, Rameix-Welti MA, Fix J, McLellan JS, Eléouët JF, Riffault S.

Nanomedicine. 2017 Feb;13(2):411-420. doi: 10.1016/j.nano.2016.08.006. Epub 2016 Aug 20.

8.

Fine mapping and characterization of the L-polymerase-binding domain of the respiratory syncytial virus phosphoprotein.

Sourimant J, Rameix-Welti MA, Gaillard AL, Chevret D, Galloux M, Gault E, Eléouët JF.

J Virol. 2015 Apr;89(8):4421-33. doi: 10.1128/JVI.03619-14. Epub 2015 Feb 4.

9.

Identification and characterization of the binding site of the respiratory syncytial virus phosphoprotein to RNA-free nucleoprotein.

Galloux M, Gabiane G, Sourimant J, Richard CA, England P, Moudjou M, Aumont-Nicaise M, Fix J, Rameix-Welti MA, Eléouët JF.

J Virol. 2015 Apr;89(7):3484-96. doi: 10.1128/JVI.03666-14. Epub 2015 Jan 7.

10.

Interactome analysis of the human respiratory syncytial virus RNA polymerase complex identifies protein chaperones as important cofactors that promote L-protein stability and RNA synthesis.

Munday DC, Wu W, Smith N, Fix J, Noton SL, Galloux M, Touzelet O, Armstrong SD, Dawson JM, Aljabr W, Easton AJ, Rameix-Welti MA, de Oliveira AP, Simabuco FM, Ventura AM, Hughes DJ, Barr JN, Fearns R, Digard P, Eléouët JF, Hiscox JA.

J Virol. 2015 Jan 15;89(2):917-30. doi: 10.1128/JVI.01783-14. Epub 2014 Oct 29.

11.

Visualizing the replication of respiratory syncytial virus in cells and in living mice.

Rameix-Welti MA, Le Goffic R, Hervé PL, Sourimant J, Rémot A, Riffault S, Yu Q, Galloux M, Gault E, Eléouët JF.

Nat Commun. 2014 Oct 3;5:5104. doi: 10.1038/ncomms6104.

PMID:
25277263
12.

Synthesis and evaluation of novel 3-C-alkylated-Neu5Ac2en derivatives as probes of influenza virus sialidase 150-loop flexibility.

Rudrawar S, Kerry PS, Rameix-Welti MA, Maggioni A, Dyason JC, Rose FJ, van der Werf S, Thomson RJ, Naffakh N, Russell RJ, von Itzstein M.

Org Biomol Chem. 2012 Nov 21;10(43):8628-39. doi: 10.1039/c2ob25627d.

PMID:
22976385
13.

Influenza virus ribonucleoprotein complexes gain preferential access to cellular export machinery through chromatin targeting.

Chase GP, Rameix-Welti MA, Zvirbliene A, Zvirblis G, Götz V, Wolff T, Naffakh N, Schwemmle M.

PLoS Pathog. 2011 Sep;7(9):e1002187. doi: 10.1371/journal.ppat.1002187. Epub 2011 Sep 1.

14.

Influenza virus infection induces the nuclear relocalization of the Hsp90 co-chaperone p23 and inhibits the glucocorticoid receptor response.

Ge X, Rameix-Welti MA, Gault E, Chase G, dos Santos Afonso E, Picard D, Schwemmle M, Naffakh N.

PLoS One. 2011;6(8):e23368. doi: 10.1371/journal.pone.0023368. Epub 2011 Aug 10.

15.

Neuraminidase of 2007-2008 influenza A(H1N1) viruses shows increased affinity for sialic acids due to the D344N substitution.

Rameix-Welti MA, Munier S, Le Gal S, Cuvelier F, Agou F, Enouf V, Naffakh N, van der Werf S.

Antivir Ther. 2011;16(4):597-603. doi: 10.3851/IMP1804.

PMID:
21685548
16.

Monitoring epidemic viral respiratory infections using one-step real-time triplex RT-PCR targeting influenza A and B viruses and respiratory syncytial virus.

Papillard-Marechal S, Enouf V, Schnuriger A, Vabret A, Macheras E, Rameix-Welti MA, Page B, Freymuth F, van der Werf S, Garbarg-Chenon A, Chevallier B, Gaillard JL, Gault E.

J Med Virol. 2011 Apr;83(4):695-701. doi: 10.1002/jmv.22006.

PMID:
21328385
17.

Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase.

Rudrawar S, Dyason JC, Rameix-Welti MA, Rose FJ, Kerry PS, Russell RJ, van der Werf S, Thomson RJ, Naffakh N, von Itzstein M.

Nat Commun. 2010 Nov 16;1:113.

18.

Enhancement of the influenza A hemagglutinin (HA)-mediated cell-cell fusion and virus entry by the viral neuraminidase (NA).

Su B, Wurtzer S, Rameix-Welti MA, Dwyer D, van der Werf S, Naffakh N, Clavel F, Labrosse B.

PLoS One. 2009 Dec 30;4(12):e8495. doi: 10.1371/journal.pone.0008495.

19.

Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome.

Bienaime F, Dragon-Durey MA, Regnier CH, Nilsson SC, Kwan WH, Blouin J, Jablonski M, Renault N, Rameix-Welti MA, Loirat C, Sautés-Fridman C, Villoutreix BO, Blom AM, Fremeaux-Bacchi V.

Kidney Int. 2010 Feb;77(4):339-49. doi: 10.1038/ki.2009.472. Epub 2009 Dec 16.

20.

Influenza A virus neuraminidase enhances meningococcal adhesion to epithelial cells through interaction with sialic acid-containing meningococcal capsules.

Rameix-Welti MA, Zarantonelli ML, Giorgini D, Ruckly C, Marasescu M, van der Werf S, Alonso JM, Naffakh N, Taha MK.

Infect Immun. 2009 Sep;77(9):3588-95. doi: 10.1128/IAI.00155-09. Epub 2009 Jun 15.

Supplemental Content

Loading ...
Support Center